The Abacus Medicine Group Announces the Nomination of Two New Members of The Board of Directors

19 September 2024

The Abacus Medicine Group today announces the nomination of two new members of The Board of Directors for Abacus Medicine A/S.

Alette Verbeek and Sharon Curran are being nominated by the main shareholders, Wagner Family Holding ApS (approx. 58% ownership) and Chr. Augustinus Fabrikker Aktieselskab (approx. 35% ownership). All shareholders have been invited to an extraordinary general meeting on 4th October, 2024.

Alette Verbeek comes with an extensive background from the pharma industry. She started her career as a pharmacist from the Leiden University in the Netherlands.

In 2011, Alette joined MSD as AVP of Global Hospital & Specialty Customer Business Line and Head of BD Europe & Canada, securing several commercial deals and partnerships.

In 2015, Alette joined Novartis in Switzerland as VP of Global BD&L for Cardiovascular, Renal, and Metabolic Disease & COVID-19 initiatives. She also spearheaded diversity and inclusion initiatives across the enterprise.

Currently, Alette Verbeek is SVP of Global Strategic Partnering & Head of EU at Zai Lab, residing in Switzerland.

Sharon Curran has an extensive background from the pharma industry. Her career has taken her through companies like Novo Nordisk, Eli Lily, Abbot and Abbvie in various commercial and strategic roles.

As Vice President of Global Marketing in Abbvie, Sharon lead franchises covering neurosciences, neurology, and niche / orphan areas.

She gained substantial strategic experience and expertise from a broad management portfolio including pricing, access, and life cycle management.

Sharon returned to Ireland in 2018 and decided to dedicate herself full time to Non-Executive roles. She is currently a board member in Norgine Ltd and Circassia Pharmaceuticals Plc.